Volume 16, Issue 9 (1-2018)
JRUMS 2018, 16(9): 891-898 |
Back to browse issues page
Faculty of Pharmacy, Kerman University of Medical Sciences
Abstract: (3635 Views)
Background and Objectives: Drug utilization evaluation of antibiotics leads to identifying drug-related problems, preventing antibiotic resistance ,and controling pharmacotherapy costs . The aim of the present study was to evaluate the use of parenteral ciprofloxacin in an inpatient setting and cost of its inappropriate use.
Materials and Methods: This cross-sectional study was conducted in Afzalipour teaching hospital in Kerman from October 2016 to December 2016. The Anatomical Therapeutic Chemical classification system and the Defined Daily Dose were used and the DDD/100 bed-days was calculated. The cost of parenteral ciprofloxacin use was also determined. Descriptive statistics and binary logistic regression were used for data analysis.
Results: One hundred and twelve patients received parenteral ciprofloxacin during the study period. The total cost of parenteral ciprofloxacin use was 13381.94 dollars. The use of parenteral ciprofloxacin in 34 (30.36%) patients was inappropriate and the cost of it was 2572.11 dollars. The dose of parenteral ciprofloxacin was not adjusted in 29 (25.89%) patients with chronic kidney disease. The overall parenteral ciprofloxacin utilization was 9.12 DDD/100 bed-days. The ratio of mean prescribed daily dose to Defined Daily Dose was 1.43.
Conclusion: The total parenteral ciprofloxacin use and also its cost were higher than other countries. So it is necessary to develop appropriative strategies to reduce its use.
Key words: Evaluation, Ciprofloxacin, Utilization, Cost, Kerman
Funding: This study was funded by Kerman University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Kerman University of Medical Sciences approved the study (IR.KMU.REC.1395.451).
How to cite this article: Dabaghzadeh F, Ebrahimi J, Arab N. Evaluation of Parenteral Ciprofloxacin Utilization and Cost in Afzalipour Hospital of Kerman in 2016: A Short Report. J Rafsanjan Univ Med Sci 2017; 16(9): 891-8. [Farsi]
Materials and Methods: This cross-sectional study was conducted in Afzalipour teaching hospital in Kerman from October 2016 to December 2016. The Anatomical Therapeutic Chemical classification system and the Defined Daily Dose were used and the DDD/100 bed-days was calculated. The cost of parenteral ciprofloxacin use was also determined. Descriptive statistics and binary logistic regression were used for data analysis.
Results: One hundred and twelve patients received parenteral ciprofloxacin during the study period. The total cost of parenteral ciprofloxacin use was 13381.94 dollars. The use of parenteral ciprofloxacin in 34 (30.36%) patients was inappropriate and the cost of it was 2572.11 dollars. The dose of parenteral ciprofloxacin was not adjusted in 29 (25.89%) patients with chronic kidney disease. The overall parenteral ciprofloxacin utilization was 9.12 DDD/100 bed-days. The ratio of mean prescribed daily dose to Defined Daily Dose was 1.43.
Conclusion: The total parenteral ciprofloxacin use and also its cost were higher than other countries. So it is necessary to develop appropriative strategies to reduce its use.
Key words: Evaluation, Ciprofloxacin, Utilization, Cost, Kerman
Funding: This study was funded by Kerman University of Medical Sciences.
Conflict of interest: None declared.
Ethical approval: The Ethics Committee of Kerman University of Medical Sciences approved the study (IR.KMU.REC.1395.451).
How to cite this article: Dabaghzadeh F, Ebrahimi J, Arab N. Evaluation of Parenteral Ciprofloxacin Utilization and Cost in Afzalipour Hospital of Kerman in 2016: A Short Report. J Rafsanjan Univ Med Sci 2017; 16(9): 891-8. [Farsi]
Type of Study: Short Report |
Subject:
Pharmacology
Received: 2017/10/17 | Accepted: 2017/11/6 | Published: 2018/01/30
Received: 2017/10/17 | Accepted: 2017/11/6 | Published: 2018/01/30
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |